Agenda
| 3:00 PM - 3:30 PM |
Registration and Networking |
| 3:30 PM - 5:00 PM |
Industry Panel |
| 5:00 PM - 6:30 PM |
Networking Reception |
Although VC's are a traditional source of funds, there are many opportunities for financing that can get your company to where you need it to be. You just need to know the right people. Join our panel to hear from government granting agencies, foundations, angels and VCs who have opportunities for you to fund your company. Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.
CONFIRMED SPEAKERS
- Jodi B. Black, PhD; MMSc, Deputy Director, Division of Extramural Research Activities, NHLBI, NIH
- Sohini Chowdhury, Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research
- Jon Mogford, PhD, Deputy Director, DARPA-Defense Sciences
- Eric Patzer, PhD, President & CEO, Aridis Pharmaceutical
- Lowell D. Ness, Corporate Partner, Orrick, Herrington & Sutcliffe LLP [Moderator]
VENUE
Orrick, Herrington & Sutcliffe LLP
1000 Marsh Road
Building 1100
Menlo Park, CA 94025-1015
Click here for Venue Directions»
SPEAKER BIOS
Jodi B. Black, PhD; MMSc, Deputy Director, Division of Extramural Research Activities, NHLBI, NIH
Dr. Black has over 20 years of scientific research and research administration experience with a diverse background in basic and clinical science, programmatic administration, and leadership. She has developed, implemented, and managed large, diverse, multidisciplinary scientific programs and projects in areas including infectious diseases, cancer and genomics, has established research resources and enhanced their utilization, has promoted training and career development, and has developed strategic alliances between academic, healthcare and commercial organizations to leverage resources and capacity across institutions. As Deputy Director, Division of Extramural Research Activities (DERA), National Heart Lung and Blood Institute, National Institutes of Health, she provides scientific and management leadership and oversight of extramural research and training programs that are remarkable in their diversity, scope, and funding. DERA scientific activities span the Institute's entire $2.8 billion research portfolio involving cardiovascular, lung, blood diseases, sleep disorders, and blood resources and encompass basic, clinical, and population-based research and training. Dr Black currently also serves as the Acting-Director of the Office of Translational Alliances and Coordination providing leadership and coordination to accelerate the translation of basic discoveries and innovations into new diagnostics, devices, and therapeutics. The Office facilitates identification of emerging areas of translational opportunities and provides functional integration by developing interdependent teams that leverage resources and intellect across the NHLBI and with other ICs, agencies, and organizations.
Sohini Chowdhury, Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research
Sohini Chowdhury joined the Foundation after spending five years at the World Economic Forum in Geneva, Switzerland. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative biotech, energy and IT technology companies into Forum activities. Ms. Chowdhury also worked directly for the Forum's CEO, acting as his liaison with key Forum stakeholders and overseeing several in-house projects. Ms. Chowdhury graduated with an MA from Georgetown University, and holds a BA in International Studies from Vassar College.
Jon Mogford, PhD, Deputy Director, DARPA-Defense Sciences
Jon Mogford is the Deputy Director in the Defense Sciences Office with interests in wound healing/regeneration, cellular therapies, tissue engineering, and vascular physiology. Dr. Mogford received his doctorate in medical sciences (physiology) from the Texas A&M Health Science Center and performed post-doctoral work at the University of Chicago. He later served as a Research Assistant Professor at Northwestern University. His research background includes studies on the role of growth factors, age, and ischemia/hypoxia on dermal wound healing/scarring and on the control of cell phenotype and microvascular function by cell adhesion receptors, growth factors, and extracellular matrix.
Eric Patzer, PhD, President & CEO, Aridis Pharmaceutical
Dr. Patzer has 22 years experience in product development beginning his career at Genentech in 1981. Dr. Patzer played a key role in the development of Activase®, Protropin®, Herceptin® and Xolair®. As Vice President, Product Development, Dr. Patzer's responsibilities included analytical development, hybridoma development, preclinical animal testing, QA/QC and project and portfolio management. Dr. Patzer played a key role in developing the product development and management process at Genentech.
In 1996 Dr. Patzer joined Aviron (now MedImmune Vaccines) as Vice President, Development. Under his leadership, the Development organization was expanded to support the development of the intranasal influenza vaccine (FluMist®) through preclinical and clinical development and resulting in U.S. regulatory approval (FDA). The organization consisted of the following departments: analytical development, clinical QC testing, process and formulation development, clinical manufacturing, clinical laboratory testing and project management. Dr. Patzer was the project team leader of the intranasal influenza vaccine, FluMist®, during preclinical and clinical development.
In 2003, Dr. Patzer founded Aridis Pharmaceuticals, LLC to develop convenient and cost effective therapeutics for infectious diseases focused on live attenuated vaccines and antibody therapies that can be delivered in simple oral or pulmonary dosage forms and that can be stored outside the cold chain (i.e., are stable at room temperature and above). Aridis is currently developing two temperature stable oral vaccines against rotavirus gastroenteritis in infants and shigellosis in adults and children and a temperature stable antibody therapeutic against pulmonary infections with Pseudomonas aeruginosa.
Lowell D. Ness, Corporate Partner, Orrick, Herrington & Sutcliffe LLP [Moderator]
Lowell Ness is a partner and a founding member of the firm’s Emerging Companies Group in the Silicon Valley Office. He has considerable experience in securities law and corporate governance matters. His practice focuses on high growth emerging companies and involves venture capital financings, mergers and acquisitions, public offerings and private placements. His clients include startup companies from the earliest stage and well established public companies. Mr. Ness also represents both private equity and venture capital funds. http://www.orrick.com/lawyers/Bio.asp?ID=19916
